Physician profile
Michelle N Watson
NPI 1922355924
$2,162.27
in general payments reported to CMS, 2019-2025
22 companies · $69.84 in 2025
The $69.84 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $905 · 2022: $678 · 2023: $397 · 2024: $112 · 2025: $69.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $553.13 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $236.33 | 2021-2024 | |
| Nevro Corp. | $197.33 | 2021-2023 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $189.09 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $165.80 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $156.10 | 2021-2022 | |
| Glaxosmithkline, LLC. | $125.34 | 2021-2024 | Trelegy Ellipta |
| Abbott Laboratories | $109.49 | 2021-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $101.12 | 2021-2022 | |
| Astellas Pharma US INC | $49.18 | 2021-2023 | Veozah |
| Dexcom, INC. | $44.13 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $35.75 | 2025 | Voquezna |
| Pfizer INC. | $32.95 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $27.97 | 2023 | Gemtesa |
| Ucb, INC. | $22.53 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $22.05 | 2021 | |
| Amarin Pharma, INC. | $20.22 | 2021 | |
| Inspire Medical Systems, INC. | $18.71 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.54 | 2021 | |
| Merck Sharp & Dohme LLC | $13.36 | 2022 | |
| Lilly USA, LLC | $12.53 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.